Skip to main content

Table 6 Idelalisib in clinical trials

From: Novel agents for chronic lymphocytic leukemia

Study agents

Other agents

Disease

Dosage

Clinical trials

No. Pts.

Response

Reference

Idelalisib

 

Relapsed

150 mg

Phase I

54

ORR:26%

[44, 45]

Refractory

Idelalisib

Rituximab

Relapsed

150 mg

Phase I

51

ORR:74/82/87%

[46]

 

Bendamustine

Refractory

   

1 year PFS:74/88/87%

 
  1. Abbreviations: ORR overall response rate, PFS progression-free survival.
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us